Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

NCT04592952 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Migraine

Interventions

DRUG: Calcitonin Gene-Related Peptide
DRUG: Erenumab

Sponsor

Danish Headache Center